CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane-induced alopecia.
Talveen S PurbaKayumba Ng'anduLars BrunkenEleanor SmartEllen MitchellNashat HassanAaron O'BrienCharlotte MellorJennifer JacksonAsim ShahmalakRalf PausPublished in: EMBO molecular medicine (2019)
Taxanes are a leading cause of severe and often permanent chemotherapy-induced alopecia. As the underlying pathobiology of taxane chemotherapy-induced alopecia remains poorly understood, we investigated how paclitaxel and docetaxel damage human scalp hair follicles in a clinically relevant ex vivo organ culture model. Paclitaxel and docetaxel induced massive mitotic defects and apoptosis in transit amplifying hair matrix keratinocytes and within epithelial stem/progenitor cell-rich outer root sheath compartments, including within Keratin 15+ cell populations, thus implicating direct damage to stem/progenitor cells as an explanation for the severity and permanence of taxane chemotherapy-induced alopecia. Moreover, by administering the CDK4/6 inhibitor palbociclib, we show that transit amplifying and stem/progenitor cells can be protected from paclitaxel cytotoxicity through G1 arrest, without premature catagen induction and additional hair follicle damage. Thus, the current study elucidates the pathobiology of taxane chemotherapy-induced alopecia, highlights the paramount importance of epithelial stem/progenitor cell-protective therapy in taxane-based oncotherapy, and provides preclinical proof-of-principle in a healthy human (mini-) organ that G1 arrest therapy can limit taxane-induced tissue damage.
Keyphrases
- chemotherapy induced
- oxidative stress
- metastatic breast cancer
- diabetic rats
- high glucose
- cell cycle
- endothelial cells
- stem cells
- drug induced
- cell therapy
- bone marrow
- endoplasmic reticulum stress
- squamous cell carcinoma
- early onset
- signaling pathway
- locally advanced
- mesenchymal stem cells
- single cell
- cell cycle arrest
- smoking cessation
- replacement therapy
- genetic diversity